DrugPatentWatch Database Preview
EXJADE Drug Profile
Which patents cover Exjade, and what generic alternatives are available?
Exjade is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has forty-eight patent family members in thirty-four countries.
The generic ingredient in EXJADE is deferasirox. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deferasirox profile page.
Summary for EXJADE
| International Patents: | 48 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 40 |
| Clinical Trials: | 28 |
| Patent Applications: | 350 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for EXJADE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for EXJADE |
| DailyMed Link: | EXJADE at DailyMed |
Pharmacology for EXJADE
| Drug Class | Iron Chelator |
| Mechanism of Action | Iron Chelating Activity Cytochrome P450 3A4 Inducers Cytochrome P450 2C8 Inhibitors Cytochrome P450 1A2 Inhibitors |
Synonyms for EXJADE
| 1044764-54-6 |
| 1133425-75-8 |
| 201530-41-8 |
| 4-((3E,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid |
| 4-((3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid |
| 4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid |
| 4-[(3E,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid |
| 4-[(3Z,5E)-3,5-Bis(6-Oxo-2,4-cyclohexadien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid, AldrichCPR |
| 4-[(3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid |
| 4-[3,5-bis(2-hydroxyphenyl) |
| 4-[3,5-Bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid |
| 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid |
| 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid |
| 4-[3,5-bis(6-oxidanylidenecyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid |
| 4-[3,5-bis(6-oxo-1-cyclohexa-2,4-dienylidene)-1,2,4-triazolidin-1-yl]benzoic acid |
| 4-{5-[(1E)-6-OXOCYCLOHEXA-2,4-DIEN-1-YLIDENE]-3-[(1Z)-6-OXOCYCLOHEXA-2,4-DIEN-1-YLIDENE]-1,2,4-TRIAZOLIDIN-1-YL}BENZOIC ACID |
| 530D418 |
| A814288 |
| AB0020007 |
| AB0073018 |
| AB01565800_02 |
| AB1008603 |
| AC-8972 |
| AC1NUU0E |
| AC1O1JMP |
| ACM1133425758 |
| AKOS015855839 |
| AKOS015902587 |
| AKOS025312553 |
| AN-5418 |
| BC677677 |
| BCP9000594 |
| BDBM50088376 |
| Benzoic acid, 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)- |
| Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]- |
| BOFQWVMAQOTZIW-UHFFFAOYSA-N |
| C21H15N3O4 |
| CAS-201530-41-8 |
| CGP-72670 |
| CHEBI:49005 |
| CHEMBL550348 |
| CS-0901 |
| CTK8F0690 |
| D03669 |
| D0Q5UQ |
| DB01609 |
| Deferasirox |
| Deferasirox (Exjade) |
| Deferasirox (JAN/USAN/INN) |
| Deferasirox [USAN:INN:JAN] |
| Deferasirox [USAN:INN] |
| Deferasirox-d4 |
| Deferasirox, ICL670 |
| Deferasiroxum |
| Deferasiroxum [INN-Latin] |
| DR002074 |
| DSSTox_CID_28522 |
| DSSTox_GSID_48596 |
| DSSTox_RID_82794 |
| DTXSID1048596 |
| Exjade (TN) |
| F0001-2380 |
| FT-0601564 |
| HE297142 |
| HE323479 |
| HMS3655A04 |
| HSDB 7844 |
| HY-17359 |
| I14-1968 |
| ICL 670 |
| ICL 670A |
| ICL-670 |
| ICL-670A |
| ICL670 |
| ICL670A |
| J-013060 |
| Jadenu |
| Jadenu (TN) |
| Jadenu Sprinkle |
| KB-49640 |
| KE-0220 |
| KS-00000G02 |
| LS-186571 |
| LS-187785 |
| MFCD09751362 |
| MFCD09951804 |
| MLS003915634 |
| MLS006010080 |
| MolPort-006-392-553 |
| MolPort-028-744-623 |
| NCGC00181754-01 |
| NCGC00263572-01 |
| PubChem20503 |
| s1712 |
| SCHEMBL1071867 |
| SCHEMBL61756 |
| SCHEMBL62042 |
| SMR002544689 |
| SR-01000931971 |
| SR-01000931971-2 |
| Tox21_112926 |
| Tox21_112926_1 |
| UNII-V8G4MOF2V9 |
| V0697 |
| V8G4MOF2V9 |
| W-5422 |
| ZINC100022643 |
| ZINC100504305 |
| ZINC100504309 |
| ZINC1481815 |
| ZINC14880008 |
US Patents and Regulatory Information for EXJADE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | EXJADE | deferasirox | TABLET, FOR SUSPENSION;ORAL | 021882-001 | Nov 2, 2005 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | |
| Novartis | EXJADE | deferasirox | TABLET, FOR SUSPENSION;ORAL | 021882-002 | Nov 2, 2005 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Novartis | EXJADE | deferasirox | TABLET, FOR SUSPENSION;ORAL | 021882-001 | Nov 2, 2005 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for EXJADE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | EXJADE | deferasirox | TABLET, FOR SUSPENSION;ORAL | 021882-001 | Nov 2, 2005 | ➤ Sign Up | ➤ Sign Up |
| Novartis | EXJADE | deferasirox | TABLET, FOR SUSPENSION;ORAL | 021882-003 | Nov 2, 2005 | ➤ Sign Up | ➤ Sign Up |
| Novartis | EXJADE | deferasirox | TABLET, FOR SUSPENSION;ORAL | 021882-002 | Nov 2, 2005 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for EXJADE
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 125 mg, 250 mg, and 500 mg | ➤ Subscribe | ➤ Sign Up |
International Patents for EXJADE
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Slovenia | 914118 | ➤ Sign Up |
| Australia | 718037 | ➤ Sign Up |
| African Intellectual Property Organization (OAPI) | 10946 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for EXJADE
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0914118/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005 |
| 2007001 | Lithuania | ➤ Sign Up | PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006 08 28, EU/1/06/356/002 2006 08 28, EU/1/06/356/003 2006 08 28, EU/1/06/356/004 2006 08 28, EU/1/06/356/005 2006 08 28, EU/1/06/356/00 20060828 |
| 0 | Finland | ➤ Sign Up | |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
